HLA ligandome tumor antigen discovery for personalized vaccine approach
Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usu...
Main Authors: | Rammensee, Hans-Georg, Singh-Jasuja, Harpreet |
---|---|
Format: | Online |
Language: | English |
Published: |
Informa Healthcare
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821395/ |
Similar Items
-
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
by: Peper, Janet Kerstin, et al.
Published: (2015) -
Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity*
by: Mommen, Geert P. M., et al.
Published: (2016) -
Human Histocompatibility Leukocyte Antigen (HLA)-G Molecules Inhibit NKAT3 Expressing Natural Killer Cells
by: Münz, Christian, et al.
Published: (1997) -
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
by: Walter, Steffen, et al.
Published: (2013) -
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors
by: Overwijk, Willem W, et al.
Published: (2013)